Daily Tadalafil and Gastric Emptying Time in Diabetic Gastroparesis
This study is currently recruiting participants.
Verified April 2013 by Duke University
Sponsor:
Mark Feinglos
Collaborators:
Duke University
Eli Lilly and Company
Information provided by (Responsible Party):
Mark Feinglos, Duke University Medical Center
ClinicalTrials.gov Identifier:
NCT01326117
First received: March 29, 2011
Last updated: April 17, 2013
Last verified: April 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The investigators hypothesize that in adult patients with diabetic gastroparesis with Type 1 diabetes (HbA1c ≤ 10.5%), daily tadalafil use will significantly improve gastric emptying compared to baseline as measured by gastric emptying time.
| Condition | Intervention | Phase |
|---|---|---|
|
Gastroparesis Diabetic Gastroparesis Nausea Vomiting |
Drug: tadalafil |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Daily Tadalafil and Gastric Emptying Time in Diabetic Gastroparesis |
Resource links provided by NLM:
MedlinePlus related topics:
Diabetes
Digestive Diseases
Nausea and Vomiting
Paralysis
Stomach Disorders
Drug Information available for:
Tadalafil
U.S. FDA Resources
Further study details as provided by Duke University:
Primary Outcome Measures:
- improvement in Gastric Emptying Study residual tracer amount [ Time Frame: 7 days with intervention ] [ Designated as safety issue: Yes ]change in gastric emptying compared to baseline as measured by gastric emptying time.
| Estimated Enrollment: | 10 |
| Study Start Date: | April 2011 |
| Estimated Study Completion Date: | December 2013 |
| Estimated Primary Completion Date: | December 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: tadalafil |
Drug: tadalafil
7 days of Cialis for Daily Use (5mg)
Other Name: Cialis
|
Eligibility| Ages Eligible for Study: | 18 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Type 1 diabetes diagnosis
- Age 18 - 65 years (inclusive)
- Hemoglobin A1c ≤ 10.5% within the last 4 months
- Diagnosis of gastroparesis, or symptoms consistent with gastroparesis (early satiety, chronic intermittent nausea or vomiting with food intake)
- Patient has gastroparesis confirmed on screening study
- A female patient is eligible to participate if she is of: Non-childbearing potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea, or child-bearing potential with negative serum hCG prior to each gastric emptying study.
Exclusion Criteria:
- Active nitrate use (e.g. Cialis, Viagra, Levitra, nitroglycerin, Isordil, Imdur, amyl nitrate/poppers)
- Fasting fingerstick glucose > 250 mg/dL
- History of abdominal surgery including gastric banding procedure
- Patient is on chronic parenteral feeding
- Patient has a history of eating disorders (anorexia nervosa, binge eating, bulimia)
- Regular opiate use
- Recent (last 6 weeks) history of poor control of diabetes e.g. hypoglycemia requiring medical intervention, diabetic ketoacidosis, admission for control diabetes or complications of diabetes
- Acute severe gastroenteritis
- The patient has participated in another clinical trial in the last 30 days.
- Use of medications potentially influencing upper gastrointestinal motility or appetite within one week of the study [e.g., prokinetic drugs, macrolide antibiotics (erythromycin), GLP-1 mimetics/analog, amylin analog]
- History or presence of clinically significant gastro-intestinal, hepatic or renal disease or other condition that would in the opinion of the investigator make the subject unsuitable for inclusion in this clinical study.
- Chronic angina or NYHA class III or IV CHF
- Concurrent use of ketoconazole or itraconazole
- History of severe vision loss, retinitis pigmentosa, or non-arteritic anterior ischemic optic neuropathy (NAION)
- History of CVA
- Pregnant females as determined by positive serum hCG test
- Lactating females
- Uncontrolled hypertension (SBP > 160 or DBP > 100)
- Hypotension (SBP < 90 or DBP < 60)
- Other major medical conditions: priapism, sickle cell anemia, multiple myeloma, leukemia, active cancer diagnosis, HIV/AIDS, alcoholism, or bleeding diathesis.
- Intolerance to active or inactive ingredients of Cialis, or intolerance to other PDE-5 inhibitors.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01326117
Locations
| United States, North Carolina | |
| Duke University Medical Center | Recruiting |
| Durham, North Carolina, United States, 27710 | |
| Contact: Kathryn J Evans, NP 919-684-3758 kathryn.evans@duke.edu | |
| Contact: Mark N Feinglos, MD, CM 919-684-4005 mark.feinglos@duke.edu | |
| Principal Investigator: Mark N Feinglos, MD, CM | |
Sponsors and Collaborators
Mark Feinglos
Duke University
Eli Lilly and Company
Investigators
| Principal Investigator: | Mark N Feinglos, MD, CM | Duke University |
More Information
No publications provided
| Responsible Party: | Mark Feinglos, Division Chief, Department of Endocrinology, Diabetes, and Metabolism, Duke University Medical Center |
| ClinicalTrials.gov Identifier: | NCT01326117 History of Changes |
| Other Study ID Numbers: | Pro00027389 |
| Study First Received: | March 29, 2011 |
| Last Updated: | April 17, 2013 |
| Health Authority: | United States: Food and Drug Administration United States: Institutional Review Board |
Keywords provided by Duke University:
|
gastroparesis gastric emptying diabetes Stomach Diseases Gastrointestinal Diseases Digestive System Diseases |
Phosphodiesterase Inhibitors Neurologic Manifestations Paralysis Signs and Symptoms Pharmacologic Actions |
Additional relevant MeSH terms:
|
Nausea Vomiting Gastroparesis Signs and Symptoms, Digestive Signs and Symptoms Stomach Diseases Gastrointestinal Diseases Digestive System Diseases Paralysis Neurologic Manifestations |
Phosphodiesterase Inhibitors Tadalafil Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Phosphodiesterase 5 Inhibitors Vasodilator Agents Cardiovascular Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on May 16, 2013